RhumbLine Advisers
NRIX icon

RhumbLine Advisers’s Nurix Therapeutics NRIX Stock Holding History

RhumbLine Advisers’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.91M Buy
123,367
+4,769
+4% +$79.1K ﹤0.01% 1883
2025
Q4 		$2.25M Buy
118,598
+4,180
+4% +$60K ﹤0.01% 1814
2025
Q3 		$1.06M Sell
114,418
-10,809
-9% -$112K ﹤0.01% 2214
2025
Q2 		$1.43M Buy
125,227
+14,739
+13% +$159K ﹤0.01% 2067
2025
Q1 		$1.31M Buy
110,488
+7,255
+7% +$121K ﹤0.01% 2042
2024
Q4 		$1.94M Buy
103,233
+12,315
+14% +$282K ﹤0.01% 1892
2024
Q3 		$2.04M Buy
90,918
+2,137
+2% +$48.4K ﹤0.01% 1901
2024
Q2 		$1.85M Buy
88,781
+11,010
+14% +$171K ﹤0.01% 1924
2024
Q1 		$1.14M Buy
77,771
+2,664
+4% +$28.7K ﹤0.01% 2181
2023
Q4 		$775K Buy
75,107
+58
+0.1% +$398 ﹤0.01% 2403
2023
Q3 		$590K Buy
75,049
+1,993
+3% +$18.2K ﹤0.01% 2515
2023
Q2 		$730K Buy
73,056
+244
+0.3% +$2.49K ﹤0.01% 2463
2023
Q1 		$647K Buy
72,812
+2,045
+3% +$21.3K ﹤0.01% 2317
2022
Q4 		$777K Buy
70,767
+677
+1% +$8.16K ﹤0.01% 2262
2022
Q3 		$913K Buy
70,090
+7,051
+11% +$112K ﹤0.01% 2177
2022
Q2 		$799K Buy
63,039
+29,528
+88% +$335K ﹤0.01% 2248
2022
Q1 		$469K Buy
33,511
+1,573
+5% +$27.9K ﹤0.01% 2448
2021
Q4 		$925K Buy
31,938
+864
+3% +$26.2K ﹤0.01% 2244
2021
Q3 		$931K Buy
31,074
+1,258
+4% +$38.8K ﹤0.01% 2251
2021
Q2 		$791K Buy
29,816
+5,601
+23% +$164K ﹤0.01% 2347
2021
Q1 		$753K Buy
24,215
+12,592
+108% +$476K ﹤0.01% 2312
2020
Q4 		$382K Buy
11,623
+2,110
+22% +$69.9K ﹤0.01% 2557
2020
Q3 		$332K Buy
+9,513
New +$240K ﹤0.01% 2467

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

RhumbLine Advisers's NRIX Position: Q1 2026 in Review

RhumbLine Advisers increased its Nurix Therapeutics (NRIX) stake by 4% in Q1 2026, buying an estimated $79.1K and bringing the position to 123,367 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1883.

RhumbLine Advisers first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $2.25M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • RhumbLine Advisers held 123,367 shares of Nurix Therapeutics worth $1.91M as of Q1 2026.
  • RhumbLine Advisers bought 4,769 Nurix Therapeutics shares in Q1 2026, an estimated $79.1K.
  • Nurix Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1883 holding.
  • RhumbLine Advisers first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • RhumbLine Advisers's Nurix Therapeutics position peaked at $2.25M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.